

Contents

List of Contributors xi

Preface xv

1. Epigenetic Biomarkers: New Findings, Perspectives, and Future Directions in Diagnostics

JOSÉ LUIS GARCÍA-GIMÉNEZ, TOSHIKAZU USHIJIMA AND TRYGVE O. TOLLEFSBOL

1. Introduction 2
2. Epigenetic Mechanisms 3
3. Epigenetic Biomarkers and In Vitro Diagnostics 8
4. Epigenetic Biomarkers and the Clinical Laboratory 10
5. Epigenetic Biomarkers: An Overview of Recent Advances 11
6. Epigenetics: Perspective of Implantation in Clinical Laboratories 12
7. Perspectives of Epigenetics in Diagnostics 14
- List of Abbreviations 15
- References 15

2. The Importance of Biobanks in Epigenetic Studies

LORENA PEIRÓ-CHOVA, OLGA BAHAMONDE RINCE, CAROLINA ABRIL-TORMO, JACOBO MARTÍNEZ-SANTAMARÍA, JOSÉ ANTONIO LÓPEZ-GUERRERO AND PETER H.J. RIEGMAN

1. Biobanks 20
2. Biobanks in Biomedical Research 24
3. Epigenetics and Biobanking 27
4. Conclusions 31
- List of Abbreviations 32
- Acknowledgments 32
- References 32

3. Epigenetic Mechanisms as Key Regulators in Disease: Clinical Implications

ABDELHALIM BOUKABA, FABIAN SANCHIS-GOMAR AND JOSÉ LUIS GARCÍA-GIMÉNEZ

1. Introduction 38
2. Epigenetics and Metabolism Intersection 42
3. Lifestyle, Nutrition, and Physical Activity in Epigenetic Regulation 45
4. Epigenetic Mechanisms Underlying Complex Diseases 47
5. Epigenetics in Rare Diseases—Clinical Implications 50
6. Epigenetic Biomarkers and Clinical Laboratory 57
7. Conclusions 58
- List of Abbreviations 58
- Acknowledgments 59
- References 59

4. The Evolution of New Technologies and Methods in Clinical Epigenetics Research

TANDY L.D. PETROV AND NICOLE C. RIDDLE

1. Introduction 68
2. DNA Methylation 69
3. Histone Modifications 74
4. Chromatin Structure 77
5. Noncoding RNAs 79
6. Conclusions and Outlook 81
- List of Abbreviations 83
- References 83

5. Biomarkers and Methodologies for Monitoring Epigenetic Drug Effects in Cancer

MARIANNE B. TREPPENDAHL, LASSE SOMMER KRISTENSEN AND KIRSTEN GRØNBÆK

1. Introduction 92
2. Predicting Response to DNMTi Treatment 95

3. Monitoring Single-Locus DNA Methylation Biomarkers in Clinical Samples 106
4. Monitoring Global DNA Methylation in Clinical Samples 110
5. Conclusions 111
- List of Abbreviations 112
- References 113

6. Genome-Wide Techniques for the Study of Clinical Epigenetic Biomarkers

ENEDA TOSKA AND F. JAVIER CARMONA SANZ

1. Introduction 119
2. First Approaches to Analyze 5-Methylcytosine Levels at a Genomic Scale 121
3. DNA Methylation Arrays 123
4. Quantification of 5mC Oxidative Derivatives 125
5. Affinity Enrichment of Methylated DNA 125
6. Reading the DNA Methylome: Genome Sequencing Applications 126
7. Conclusions 131
- List of Abbreviations 132
- Acknowledgments 132
- References 132

7. Sequenom MassARRAY Technology for the Analysis of DNA Methylation: Clinical Applications

ENRIQUE J. BUSÓ AND MARISA IBORRA

1. Introduction 138
2. DNA Methylation 138
3. Methods for DNA Methylation Analysis 138
4. DNA Methylation Studies by Sequenom 146
5. Conclusions 150
- Glossary 151
- List of Abbreviations 151
- References 151

8. The Role of Methylation-Specific PCR and Associated Techniques in Clinical Diagnostics

FANG ZHAO AND BHARATI BAPAT

1. Overview of DNA Methylation as an Epigenetic Marker 156
2. DNA Methylation in Diagnostics 156
3. Restriction Enzyme Digestion for Analyzing DNA Methylation 158

4. Methylation-Specific PCR and Associated Techniques 158
5. Sodium Bisulfite Conversion 158
6. Methylation-Specific PCR 158
7. Methylation-Sensitive Dot Blot Assay 162
8. MethyLight 162
9. Technical Specifications for MethyLight 163
10. Applications of MethyLight Technique 163
11. Multiplex MethyLight 164
12. Methylation-Sensitive Multiplex Ligation-Dependent Probe Amplification 167
13. Pyrosequencing 167
14. High-Resolution Melting Analysis 168
15. Emerging Applications 168
16. Future of DNA Methylation in Clinical Applications 169
- List of Abbreviations 170
- Acknowledgment and Funding Support 170
- References 170

9. Pyrosequencing and Its Application in Epigenetic Clinical Diagnostics

ANA-MARIA FLOREA

1. Introduction 175
2. Detection of Epigenetic Changes By Pyrosequencing: DNA Methylation 177
3. Pyrosequencing and the Assessment to miRNAs 189
4. Conclusions 190
- Glossary 191
- List of Abbreviations 191
- References 192

10. Mass Spectrometry for the Identification of Posttranslational Modifications in Histones and Its Application in Clinical Epigenetics

ROBERTA NOBERINI, ALESSANDRO CUOMO AND TIZIANA BONALDI

1. Introduction 196
2. MS Analysis of hPTMs 197
3. Toward Clinical Applications of MS Analysis of hPTMs 203
4. Conclusions and Perspectives 208
- List of Abbreviations 209
- Acknowledgments 209
- References 209

11. High-Throughput Analysis of Noncoding RNAs: Implications in Clinical Epigenetics

VALERIO COSTA, MARIA R. MATARAZZO,
WILLIAM GAGLIARDI, ROBERTA ESPOSITO AND
ALFREDO CICCOCICOLA

1. Introduction 216
2. ncRNAs: Definitions and Innovative Technologies for Their Analysis 216
3. How the Epigenome Controls ncRNAs and How ncRNAs Control the Epigenome 221
4. ncRNAs and Epigenetics: Clinical Relevance 224
5. Conclusions and Future Perspectives 231
- Glossary 232
- List of Abbreviations 233
- References 233

12. Circulating Noncoding RNAs as Clinical Biomarkers

FRANCESCO RUSSO, FLAVIA SCOYNI,
ALESSANDRO FATICA, MARCO PELLEGRINI,
ALFREDO FERRO, ALFREDO PULVIRENTI AND
ROSALBA GIUGNO

1. Introduction 240
2. MicroRNAs 242
3. Long Noncoding RNAs 245
4. Circular RNAs 249
5. Resources for Circulating RNAs 250
6. Conclusion and Future Perspective 252
- List of Abbreviations 253
- Acknowledgments 253
- References 253

13. DNA Methylation Biomarkers in Lung Cancer

JUAN SANDOVAL AND PAULA LOPEZ SERRA

1. Introduction 259
2. Methylation 260
3. Epigenetic-Associated Regulatory Elements 261
4. DNA Methylation in Cancer 263
5. DNA Methylation in Lung Cancer 263
6. Conclusions 269
- List of Abbreviations 270
- References 270

14. DNA Methylation Alterations as Biomarkers for Prostate Cancer

JOÃO RAMALHO-CARVALHO, RUI HENRIQUE AND
CARMEN JERÓNIMO

1. Introduction 275
2. The Aberrant DNA Methylation Landscape of PCa 279
3. Promoter Hypermethylation in PCa 280
4. Hypomethylation in PCa 282
5. DNA Methylation-Based Markers for PCa Detection, Management, and Risk Estimation 285
6. Cancer Detection and Diagnosis 285
7. Prognosis and Prediction of Response to Therapy 287
8. Conclusions and Perspectives 288
- Glossary 290
- List of Abbreviations 291
- References 291

15. DNA Methylation in Breast Cancer

RAIMUNDO CERVERA, ALBERTO RAMOS, ANA LLUCH
AND JOAN CLIMENT

1. Introduction 297
2. Major Milestones in Breast Cancer and DNA Methylation Research 298
3. DNA Methylation 300
4. DNA Methylation as a Therapeutic Target 306
5. Concluding Remarks and Future Prospects 307
- List of Abbreviations 308
- References 308

16. DNA Methylation in Obesity and Associated Diseases

ANA B. CRUJEIRAS AND ANGEL DIAZ-LAGARES

1. Introduction 313
2. An Overview of Epigenetics: Focus on DNA Methylation 314
3. Environmental and Lifestyle Factors Influencing DNA Methylation 316
4. DNA Methylation Pattern and Obesity Susceptibility 317
5. Epigenetics as a Link between Obesity and Its Codiseases 318
6. DNA Methylation as Biomarker of Disease 319
7. Epigenetic Drugs and Functional Foods for Overcoming Metabolic Diseases 323

8. Conclusion 324
 List of Abbreviations 325
 References 325

17. DNA Methylation Biomarkers in Asthma and Allergy

AVERY DeVRIES AND DONATA VERCELLI

1. Introduction 331
 2. Allergic Diseases: Phenotypes and Genes 332
 3. Why Has Epigenetics Become a Buzz Word in Allergic Disease? 333
 4. What Have We Learned So Far from Allergic Disease Epigenetics? 334
 5. Conclusion: Where Is the Field Going? 347
 List of Abbreviations 348
 References 348

18. DNA Methylation for Prediction of Adverse Pregnancy Outcomes

DEEPAI SUNDRANI, VINITA KHOT AND SADHANA JOSHI

1. Introduction 352
 2. Epigenetics 352
 3. Epigenetic Mechanisms 353
 4. Regulation of Gene Expression by Epigenetic Mechanisms 354
 5. Epigenetic Changes during the Mammalian Life Cycle 354
 6. DNA Methylation during Embryonic Development 355
 7. Maternal Nutrition, DOHaD, and Epigenetics 356
 8. Epigenetic Regulation in the Placenta and Adverse Pregnancy Complications 360
 9. Conclusion and Future Prospects 365
 Glossary 369
 List of Abbreviations 370
 References 371

19. Epigenetics in Infectious Diseases

GENEVIEVE SYN, JENEFER M. BLACKWELL AND SARRA E. JAMIESON

1. Introduction 377
 2. miRNA Profiles 386
 3. DNA Methylation Patterns 388
 4. Histone Marks 391
 5. Concluding Remarks 394
 Glossary 394

- List of Acronyms and Abbreviations 395
 References 395

20. DNA Methylation in Neurodegenerative Diseases

SAHAR AL-MAHDAWI, SARA ANJOMANI VIRMOUNI AND MARK A. POOK

1. Introduction 401
 2. DNA Methylation and the CNS 403
 3. Alzheimer's Disease 404
 4. Parkinson's Disease 406
 5. Amyotrophic Lateral Sclerosis 406
 6. Huntington's Disease 408
 7. Fragile X-Associated Tremor/Ataxia Syndrome 409
 8. Friedreich Ataxia 409
 9. Spinocerebellar Ataxia 7 410
 10. Conclusion 410
 List of Abbreviations 412
 References 412

21. The Histone Code and Disease: Posttranslational Modifications as Potential Prognostic Factors for Clinical Diagnosis

NICOLAS G. SIMONET, GEORGE RASTI AND ALEJANDRO VAQUERO

1. Introduction 418
 2. Histone Modifications and Disease 426
 3. Conclusions 438
 Glossary 438
 List of Abbreviations 438
 References 439

22. Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer

FILIPA QUINTELA VIEIRA, DIOGO ALMEIDA-RIOS, INÊS GRAÇA, RUI HENRIQUE AND CARMEN JERÓNIMO

1. Introduction 448
 2. Epigenetic-Based Markers for PCa Detection, Management, and Risk Estimation 451
 3. Epigenetic Silencing as a Therapeutic Target in PCa 454
 4. Conclusion 459
 Glossary 460
 List of Abbreviations 460
 References 461

23. Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis

LUIGI MAGNANI, ANNITA LOULOUPI AND WILBERT ZWART

1. Histone Marks and the Epigenetic Landscape 468
2. Breast Cancer Subtypes, Hormonal Dependence, and Epigenetic Regulation 468
3. Epigenetic Factors in Mammary Gland Development and Cancer 469
4. Epigenetic Complexes as Mutational Targets in Luminal Breast Cancer 471
5. Epigenetic Modifications as Biomarkers for Treatment Sensitivity and Outcome 471
6. Epigenetic Modifiers as Potential Drug Targets in Cancer 473
7. Conclusive Remarks 474
- Glossary 474
- List of Abbreviations 475
- References 475

24. Histone Variants and Posttranslational Modifications in Spermatogenesis and Infertility

LUIGI MAGNANI, YINAN ZHANG AND TOYOTAKA ISHIBASHI

1. Introduction 480
2. Histone Variants and their Role in Infertility 481
3. The Effects of Histone PTMs 489
4. Brief Overview of the Role of Spermiogenesis-Specific Nuclear Basic Proteins: TNP and Protamines in Infertility 490
5. Can Histone Variants be Used as Biomarkers for Infertility? 491
6. Closing Remarks 492
- Glossary 492
- List of Abbreviations 493
- Acknowledgments 493
- References 493

25. Circulating Histones and Nucleosomes as Biomarkers in Sepsis and Septic Shock

ISABEL GARCÍA GIMÉNEZ, CARLOS ROMÁ MATEO, MARTA SANCHEZ, JOSÉ SANTIAGO IBÁÑEZ CABELLOS AND FEDERICO V. PALLARDÓ

1. Introduction 498
2. Epidemiology and Clinical Features of Sepsis, Severe Sepsis, and Septic Shock 499

3. Genetics, Epigenetics, and Molecular Pathways Underlying Sepsis 500
4. Extracellular Nucleosomes and Histones and Their Role in the Pathophysiology of Sepsis and Septic Shock 503
5. Circulating Histones as Biomarkers of Prognosis and Treatment Monitoring 507
6. Therapeutic Approaches to Antagonize Histone-Mediated Toxicity 510
7. Conclusions 513
- Glossary 513
- List of Abbreviations 513
- Acknowledgments 513
- References 513

26. Chromatin Landscape and Epigenetic Signatures in Neurological Disorders: Emerging Perspectives for Biological and Clinical Research

PAMELA MILANI AND ERNEST FRAENKEL

1. Introduction 520
2. The Involvement of Epigenetic Modifications in HD 520
3. The Involvement of Epigenetic Modifications in ALS 526
4. Conclusions and Future Perspectives 531
- Glossary 533
- List of Abbreviations 533
- Acknowledgments 533
- References 534

27. MicroRNA Deregulation in Lung Cancer and Their Use as Clinical Tools

PAULA LOPEZ-SERRA AND JUAN SANDOVAL

1. Introduction to Noncoding RNA in Human Cell Physiology 540
2. miRNA Biology and Mechanism of Action 541
3. miRNA Alteration in Lung Cancer Progression 543
4. miRNA-Based Biomarkers for Lung Cancer Diagnosis, Prognosis, and Treatment 545
5. Interplay between Genetics and Epigenetics in miRNA Regulation and Lung Cancer 549
6. miRNA-Based Anticancer Therapy 551
7. Concluding Remarks 551
- List of Abbreviations 552
- References 552

28. Circulating Nucleic Acids as Prostate Cancer Biomarkers

CLAIRE E. FLETCHER, AILSA SITA-LUMSDEN, AKIFUMI SHIBAKAWA AND CHARLOTTE L. BEVAN

1. Introduction—The Urgent Requirement for New Prostate Cancer Biomarkers 557
 2. Circulating miRNAs as Biomarkers 559
 3. Circulating mRNAs as Biomarkers 563
 4. Cell-Free DNAs as Biomarkers 565
 5. Conclusions 569
- List of Abbreviations 580
Acknowledgments 580
References 580

29. MicroRNAs in Breast Cancer and Their Value as Biomarkers

OLAFUR ANDRI STEFANSSON

1. Introduction 588
 2. Global Deregulation of miRNAs in Cancer 590
 3. The Biological Significance of miRNAs in Breast Cancer Development 590
 4. Genetic Variants in miRNAs and Their Binding Sites 592
 5. Acquired Genomic and Epigenomic Changes Affecting miRNAs 596
 6. miRNAs as Regulators of the DNA Damage Response 597
 7. DNA Repair Genes as Targets of miRNAs: A Bridge toward Personalized Treatment? 598
 8. miRNAs as Prognostic Biomarkers 600
 9. The Use of miRNAs in Screening for Early Breast Cancer Development 604
 10. Conclusions 604
- Glossary 606
List of Abbreviations 606
Acknowledgments 606
References 606

30. MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers

TOMOHIRO FUJIWARA, YU FUJITA, YUTAKA NEZU, AKIRA KAWAI, TOSHIFUMI OZAKI AND TAKAHIRO OCHIYA

1. Introduction 614
 2. miRNAs in Bone Sarcomas 615
 3. miRNAs in Soft Tissue Sarcomas 624
 4. Circulating miRNAs in Bone and Soft Tissue Sarcomas 632
 5. Conclusions 633
- List of Abbreviations 635
Acknowledgment 635
References 635

31. miRNAs in the Pathophysiology of Diabetes and Their Value as Biomarkers

EOIN BRENNAN, AARON MCCLELLAND, SHINJI HAGIWARA, CATHERINE GODSON AND PHILLIP KANTHARIDIS

1. Introduction 644
 2. miRNAs Regulating Pancreatic β -Cell Function and Insulin Secretion 646
 3. miRNAs in Insulin Target Tissues: Liver, Skeletal Muscle, and Adipose Tissue 648
 4. miRNA Responses to Antidiabetic Therapies 652
 5. Pharmacological Targeting of miRNAs in Diabetes 653
 6. Circulating miRNAs as Promising Clinical Biomarkers for Diabetes 654
 7. Conclusion 656
- List of Abbreviations 657
References 657

Index 663